2025 Successes and What They Signal for 2026
Regulatory expectations accelerated in 2025. As FDA scrutiny increased, many innovative medical device companies encountered regulatory challenges that threatened timelines, funding, and market plans. MethodSense was engaged to restore regulatory confidence, reduce execution risk, and reestablish momentum. In this newsletter, you will learn about how MethodSense is turned these lessons into valuable information for your business and greater success in 2026.
Setting the Stage for 2026
FDA Workload and Early Review Timelines
2026 began with the FDA carrying a heavy workload, with late year submissions and the prior government shutdown compressing early review capacity. As a result, the Agency faced challenges meeting early interaction timelines.
Anticipating this environment, MethodSense proactively engaged assigned reviewers and structured Additional Information Needed (AINN) responses so progress was not dependent on Agency timing. This practice allows teams to continue advancing work, reducing downstream schedule risk and avoiding reactive decisions later in review.
Regulatory Priorities Are Clear
The FDA’s expectations remain consistent, with continued emphasis on Human Factors, Cybersecurity, and quality systems grounded in risk management. These areas are often most challenging in practice, particularly for legacy systems and complex devices.
In 2025, all MethodSense supported submissions were completed successfully, many involving legacy architectures with significant cybersecurity constraints and complex Human Factors studies. Each device was treated as a unique regulatory scenario, with strategy and evidence tailored to the specific device, user population, and risk profile. By addressing these priorities early and deliberately, we removed uncertainty from review and enabled predictable timelines with limited, focused feedback . If you have an FDA review letter observations on these topics and want help developing a structured, optimized response, we can help.
QMSR in Practice: What Made the Difference
With QMSR taking effect in early 2026, FDA inspections have shifted toward a deeper examination of integration of risk management across the quality system. Clients using LuminLogic benefited from risk management embedded into its features, proactive system updates and continuous improvement informed by hands on regulatory experience, not reactive remediation.
MethodSense recently supported a full FDA inspection under this new framework. What began as a standard inspection extended across five intensive days of detailed review. LuminLogic’s integrated Quality Management System enabled precise, evidence-based responses to every auditor inquiry. Because risk management is integrated within CAPAs, complaints, change control, and supplier management, the team moved seamlessly across records and demonstrated complete traceability without delay. Comprehensive audit trails and validated electronic signatures allowed timelines to be verified with certainty and decisions to be substantiated with objective data. This capability was critical in supporting the client remotely while maintaining full transparency to the investigator. The inspection concluded with zero Form 483 observations . Please contact us for a demo when you want to see LuminLogic in action.
Expanding Inspection Activity and the Role of ELSA
Inspection activity continues to expand, including unannounced inspections for lower risk and exempt devices based on risk profiles. As FDA Commissioner Marty Makary, M.D., M.P.H. recently noted, “we also use AI to help inspectors identify high-yield inspection targets,” reinforcing the Agency’s shift toward more data- and risk-informed oversight. FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People | FDA.
MethodSense 2025 Successes That Matter
Regulatory confidence across complex technologies
MethodSense supported successful devices across neurology, cardiology, dentistry, orthopedics, general hospital, in vitro diagnostics, and imaging, including multiple AI enabled technologies. These efforts included first of kind submissions, novel indications, and major device modifications.
Clear FDA alignment for novel devices
For innovative devices without established precedent, we pressure tested strategies through FDA pre-submissions. Early alignment confirmed critical assumptions and, in several cases, directly changed development direction, reducing late stage redesign and investor risk.
Predictable submissions in a constrained FDA environment
Innovative and AI enabled submissions progressed through review within expected timelines despite increased Agency workload, supported by targeted regulatory framing and disciplined biostatistical rationale enabling companies to meet investor milestones.
Human Factors without downstream remediation
All Human Factors studies were completed successfully, including complex workflows and high-risk use scenarios. Early planning, clear use related risk analysis, and creative study designs informed by deep product knowledge and FDA expectations resulted in acceptance without additional testing.
Cybersecurity accepted as submitted
Cybersecurity strategies for legacy and connected devices were accepted without rework, despite heightened scrutiny for AI enabled and connected systems.
Quality systems built for inspection
Risk based Quality Management Systems implemented within LuminLogic supported inspection readiness and QMSR transition without reactive remediation.
LuminLogic Platform and Thought Leadership
LuminLogic is a regulatory intelligence platform designed around real industry practice. Decades of regulatory experience are embedded into the system to support scalable operations, predictable submissions, and inspection ready compliance aligned with today’s FDA expectations.
The MedTech Smarts with Rita podcast launched in 2025, covering AI in medical devices, Human Factors, Cybersecurity, FDA digital submissions, and regulatory strategy for innovators. View the podcast series.
MethodSense Investor and Capital Strategy Services in 2026
In 2026, investor expectations are increasingly shaped by regulatory readiness, execution risk, and predictable outcomes. To support this need, MethodSense expanded its services under Chief Growth Officer Richard Holcomb , who brings more than 30 years of experience raising over $100 million in growth capital and participating in hundreds of millions of dollars in M&A transactions.
This offering supports early-stage fundraising, institutional investment, strategic partnerships, and exit planning, and extends to investor clients seeking diligence and portfolio guidance . Learn about the new service.
Winning in 2026
Success in 2026 will favor companies that recognize regulatory success requires both infrastructure and experience. Early planning, risk driven design, proactive FDA alignment, and sufficient capital create predictable execution. Regulatory rigor and speed are not tradeoffs.
When LuminLogic is combined with MethodSense expertise, companies achieve regulatory compliance with confidence. Regulatory knowledge, decisions, and evidence are captured systematically in one place, protecting intellectual property, supporting diligence, and strengthening exit readiness. This combination reduces uncertainty, accelerates timelines, and increases enterprise value as companies scale toward acquisition or investment.